Internal Medicine
SR/MA: Colistin nephrotoxicity
5 Feb, 2021 | 01:21h | UTC
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
COVID’s mental-health toll: how scientists are tracking a surge in depression
5 Feb, 2021 | 01:36h | UTCCOVID’s mental-health toll: how scientists are tracking a surge in depression – Nature
Related: Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic – JAMA Psychiatry AND Mental Health, COVID-19, and the Invisible Pandemic on the Horizon – Mayo Clinic Proceedings
State of the Art Review: Uveitis for the non-ophthalmologist
4 Feb, 2021 | 01:22h | UTCUveitis for the non-ophthalmologist – The BMJ (free for a limited period)
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
Observational study suggests a conservative approach to inpatient hypertension may be safer
4 Feb, 2021 | 01:14h | UTCTreatment and Outcomes of Inpatient Hypertension Among Adults With Noncardiac Admissions – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
#Hypertension is common in the inpatient setting, but antihypertensive intensification is not. Intensification of therapy without signs of end-organ damage is associated with worse outcomes https://t.co/y1MdZNfi9P
— JAMA Internal Medicine (@JAMAInternalMed) December 29, 2020
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
4 Feb, 2021 | 01:32h | UTCCommentary: Covid: Antibodies last at least six months in most – BBC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission
4 Feb, 2021 | 01:35h | UTCCommentary: Understanding the drivers of transmission of SARS-CoV-2 – The Lancet Infectious Diseases
[Preprint] Meta-analysis: More than 50 Long-term effects of COVID-19
4 Feb, 2021 | 01:26h | UTCMore than 50 Long-term effects of COVID-19: a systematic review and meta-analysis – medRxiv
Commentary: 80% of COVID-19 Patients May Have Lingering Symptoms, Signs — More than 50 effects persisted after acute infection, meta-analysis shows – MedPage Today (free registration required)
Systematic review: No evidence that patients with asthma are at increased risk of COVID-19 diagnosis, hospitalization or death
4 Feb, 2021 | 01:24h | UTC
USPSTF recommends against screening for asymptomatic carotid artery stenosis in the general adult population
3 Feb, 2021 | 01:29h | UTCEditorials: Screening for Asymptomatic Carotid Artery Stenosis: Lack of Clinical Benefit, Potential for Harm – JAMA AND Screening for Asymptomatic Carotid Artery Stenosis in Adult Patients: Unclear Benefit but Downstream Risks – JAMA Internal Medicine AND USPSTF Recommendations for Screening for Carotid Stenosis to Prevent Stroke—The Need for More Data – JAMA Network Open
Author interview: USPSTF Recommendation: Carotid Artery Stenosis
JAMA Patient Page: Screening for Carotid Artery Stenosis
Atrial fibrillation in low- and middle-income countries: a narrative review
3 Feb, 2021 | 01:23h | UTCAtrial fibrillation in low- and middle-income countries: a narrative review – European Heart Journal
Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective
3 Feb, 2021 | 01:49h | UTCCommentaries: Sputnik V COVID-19 vaccine candidate appears safe and effective – The Lancet AND Russia’s “Sputnik V” COVID Vaccine Makes Strong 91.6 % Efficacy Showing In Peer-Reviewed Trial Results – Health Policy Watch AND Russia’s COVID vaccine 92% effective, even in those over 60 – CIDRAP AND Russia’s Sputnik V vaccine has 92% efficacy in trial – BBC AND Expert reaction to study looking at preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine (Sputnik) trial – Science Media Centre
Commentary on Twitter
NEW—Interim analysis of Russian #COVID19 #vaccine phase 3 trial involving nearly 20,000 participants suggests a two-dose regimen has an efficacy of 91.6% against symptomatic #COVID19. No serious adverse events were deemed to be associated with vaccination. https://t.co/40sM7f2nbS pic.twitter.com/Hzrs34uCWr
— The Lancet (@TheLancet) February 2, 2021
Covid-19: People who have had infection might only need one dose of mRNA vaccine
3 Feb, 2021 | 01:44h | UTCCovid-19: People who have had infection might only need one dose of mRNA vaccine – The BMJ
Original preprint studies: Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine – medRxiv AND Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 – medRxiv
One in three adults report anxiety, depression related to COVID-19
3 Feb, 2021 | 01:35h | UTCOne in three adults report anxiety, depression related to COVID-19 – Duke-NUS Medical School
Podcast: Hypertension Update
2 Feb, 2021 | 01:07h | UTC#254 Hypertension Update with Dr. Wanpen Vongpatanasin – The Curbsiders Internal Medicine Podcast
Ambulatory management of pulmonary embolism: A comparison of two risk-stratification scores
2 Feb, 2021 | 01:11h | UTC
Resumption of cardiac activity after withdrawal of life-sustaining measures
2 Feb, 2021 | 01:09h | UTCResumption of Cardiac Activity after Withdrawal of Life-Sustaining Measures – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: When is ‘dead’ really dead? What happens after a person ‘flatlines’ – The Conversation
Coccidioidomycosis: a review
2 Feb, 2021 | 01:04h | UTCCoccidioidomycosis: a review – Journal of Investigative Medicine
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
2 Feb, 2021 | 01:19h | UTCOriginal Study: Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia – Radiology
COVID-19 rarely spreads through surfaces. So why are we still deep cleaning?
2 Feb, 2021 | 01:20h | UTCCOVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature
COVID-19 vaccine-linked adenopathies could mimic breast malignancies
2 Feb, 2021 | 01:17h | UTCCOVID-19 Vaccine-Linked Adenopathies Could Mimic Breast Malignancies – Diagnostic Imaging
Original Study: Unilateral axillary Adenopathy in the setting of COVID-19 vaccine – Clinical Imaging
Commentaries on Twitter
Important for radiologists to consider vaccine induced hyperplastic adenopathy in unilateral axillary adenopathy seen on #breastimaging post #COVID19Vaccine #COVID19
Read here https://t.co/7IizHgIzU0@NishiMehtaMD @KatiaDodelzon @KemiMDRad @WCMRadiology @BreastImaging
— Clinical Imaging (@CI_Journal) January 19, 2021
The COVID-19 vaccine may cause swollen lymph nodes that could be mistaken for breast malignancies. However, it's important not to postpone your vaccine or breast cancer screenings, researchers from @WCMRadiology and @WCMBreastCenter say. https://t.co/jLuVbA2rXL
— Weill Cornell Medicine (@WeillCornell) January 22, 2021
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial